obovadugibe.blogspot.com
Genzyme (NASDAQ: GENZ) found a viruz strain and stopped production of two drugs atthe Mass., facility. The Vesivirus 2117, apparently does not causr human infection but interrupts the growth of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fata disease caused by an enzymwe deficiency — was last filled at the Genzyme facilitt in September 2008, accordinyg to BioMarin (NASDAQ: BMRN). The companyy has about 10 months of vialed inventory on it said, and uses a second fill finish A third supplier is expected to be qualified late r this year, BioMarin said. BioMarin makes the bulk material used in Aldurazymes at itsNovato facility.
The Food and Drug Administratiomn hadinspected Genzyme’s plant in Septemberf and October and reportedly was concernee about controls to protect against
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment